The Pharmacist in the Acute Geriatric Inpatient Treatment Team

Conditions Unspecified Clinical Trial

— AGITATE  

Official title:

The Pharmacist in the Acute Geriatric Inpatient Treatment Team - Impact on Re-hospitalization and Trans-sectoral Communication

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03412903
• Other study ID #: 17-137
• Secondary ID: EK 230/17
• Status: Completed
• Start date: January 22, 2018
• Est. completion date: April 3, 2020

Study information

• Verified date: July 2020
• Source: RWTH Aachen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This trial investigates the effects of a comprehensive pharmaceutical assessment in an acute care geriatric hospital on the number of hospital readmissions and patient's days spent at home.

Description:

Drug-related problems are common in elderly patients. These problems can not only be regarded from a medical or economical point of view (i.e. hospitalization, drug related deaths, longer hospital stays and increased healthcare costs) but also from a patient centered perspective: Drug therapy may not be sufficiently explained by health care practitioners, patients might suffer from side effects, the number of different medications could be too large and their intake schedule too difficult, all of this leading to a reduced adherence. In addition, medication histories are rarely accurate in older patients and doctor's letters do not always meet the requirements of a complex drug therapy. At the transition from inpatient to outpatient treatment this can lead to a significant loss of information and subsequently cause patient harm.

In Germany, clinical, ward-based pharmacists are not yet established in contrast to other countries (i.e. Great Britain, Canada and Australia). However, the implementation of a clinical pharmacist may particularly address the problems described above. The present study therefore describes the implementation of a comprehensive pharmaceutical assessment in an acute care geriatric hospital.

The above mentioned pharmaceutical assessment consists of the following steps:

First, the pharmacist will obtain the patient's medication history following the protocol of "best possible medication history" (WHO). Furthermore, he will ascertain the patient's adherence to his/her drug regime. With the information obtained, he will then carry out a thorough medication review (regarding interactions, contraindications, suitability for the elderly, dosage regimes, etc.) in order to develop a suggestion for the best possible drug regime, which is discussed with the treating physician. In addition, he will also observe possible side effects and provide information on the background and significance of every single drug to the patient and/or his/her care-giver. Furthermore, the handling of difficult devices (i.e. insulin pens, inhalators and transdermal therapeutic systems) will be individually explained. Finally, the pharmacist will prepare a distinctive paragraph in the medical discharge report in which he explains the changes in the medication regime during the inpatient period to the general practitioner and will also elaborate possible interactions and problems concerning the patient's medication (pharmaceutical council).

The main outcome to be evaluated will be the number of hospital readmissions and drug related hospital readmissions within six months after discharge (recorded at one, three and six months). The secondary outcome will be the days spent at home (also recorded at one, three and six months), time to readmission, changes in medication within six months and the acceptance of the supposed medication regime by the general practitioner (GP).

The study will be conducted as a before and after comparison in which the steps described above will be implemented successively: In the first phase (140 patients planned for an observation period of eight months), patients will receive standard care and the pharmacist will only obtain the medication history shortly after admission. Results and discrepancies will be discussed with the attending physician of the hospital. After discharge, described outcomes will be documented. In the second phase (140 patients planned for an observation period of eight months), the pharmacist will conduct all of the activities described above. The outcomes will be documented as in phase one.

We expect that the comprehensive pharmaceutical assessment in the second phase will lead to a better coordination regarding the medication regime, enhance the patient's knowledge of their medication, thus improving their adherence to the therapy and that the pharmaceutical council will ensure a better trans-sectoral communication to the GP with a higher acceptance of the supposed drug regime in the doctor's letter. All these improvements combined might reduce hospital readmissions and increase the patient's days spent at home.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 154
• Est. completion date: April 3, 2020
• Est. primary completion date: September 20, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

• Geriatric complex treatment (Operation and procedure code (German: "Operationen- und Prozedurenschlüssel", OPS) 8-550)

• In-patient stay for at least 7 days

• Written informed consent of the patient or the legal representative

• Existing concomitant drug therapy at the time of the inpatient admission

Exclusion Criteria:

• Patients, that were already included in the study beforehand

• Patients classified as terminally ill by the medical staff

• Patients, that are incapable to give their informed consent and who do not have a legal representative

Related Conditions & MeSH terms

• Conditions Unspecified
• Pharmacists in Geriatric Health Services

Locations

Country	Name	City	State
Germany	Franziskushospital	Aachen	Northrheinwestfalia

Sponsors (1)

Lead Sponsor	Collaborator
Prof. Dr. med. Cornelius Bollheimer

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Drug related re-hospitalization	Number of re-hospitalizations with causal relation to one or more medicinal products, to examine the potential effect of an advising pharmacist	6 months
Secondary	Overall re-hospitalization	Overall number of re-hospitalizations within the observational period per patient	6 months
Secondary	Days spent at home	Number of days within the observational period not spent in a hospital, short-term care facility, rehabilitation centre, day-care hospital, emergency department or other medical facilities	6 months
Secondary	Period of time until the potential re-hospitalization into the inpatient sector	Time between the discharge and a potential re-hospitalization per patient	6 months
Secondary	Acceptance of the recommended medication plan by the further treating primary care physicians	Adoption of the medication plan, recommended in the doctor's letter, by the further treating primary care physicians	6 months
Secondary	Time required for the pharmacists support	Expenditure of time, required for the pharmacists support, per patient within the implementation group	6 months
Secondary	Completeness of the pharmaceutical anamnesis in the course of the inpatient admission	Comparison between the pharmaceutical anamnesis conducted by the doctor and the pharmacist, respectively	6 months
Secondary	Evaluation of the clinical relevance of the medicinal products, which were not assessed by the doctors	The evaluation will be conducted by an interdisciplinary group using the focus group method.	6 months